Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs.

Keyphrases

• Nanoparticulate 100%
• Paclitaxel 100%
• Healthy Dogs 100%
• Dose Escalation 100%
• Safety Study 100%
• Pharmacokinetics 66%
• Dose-limiting Toxicity 66%
• Tumor 33%
• Surfactant 33%
• High Dose 33%
• Kidney 33%
• Liver 33%
• Maximum Tolerated Dose 33%
• Euthanized 33%
• Complete Blood Count 33%
• Highly Effective 33%
• Normal Adults 33%
• Necropsy 33%
• Gastrointestinal Toxicity 33%
• Physical Assessment 33%
• Phase II Trial 33%
• Adverse Events 33%
• Neutropenia 33%
• Hounds 33%
• Laboratory Evaluation 33%
• Urinalysis 33%
• Normal Saline 33%
• Solubilizing Agent 33%
• Maximum Tolerated 33%
• Spleen Toxicity 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Paclitaxel 100%
• Maximum Tolerated Dose 66%
• Pharmacokinetics 66%
• Malignant Neoplasm 33%
• Neoplasm 33%
• Surfactant 33%
• Sodium Chloride 33%
• Gastrointestinal Toxicity 33%
• Neutropenia 33%
• Adverse Event 33%
• Solubilizer 33%